Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ketotifen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 6/20 | 1.00 |
| ▸ | DRD3 | P35462 | 7/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 5/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 4/20 | 1.00 |
| ▸ | HTR2A | P28223 | 4/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
| ▸ | DRD2 | P14416 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | HTR3A | P46098 | 3/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 3/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 3/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
| ▸ | HTR7 | P34969 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | DRD5 | P21918 | 1/20 | 1.00 |
| ▸ | HTR1B | P28222 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ketotifen SCHEMBL8809 | 1.00 | DRD3 (1.00) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL29400782 | 1.00 | DRD3 (1.00) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL1170677 | 1.00 | DRD3 (1.00) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL226911 | 1.00 | DRD3 (1.00) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL27443523 | 1.00 | DRD3 (1.00) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL27685749 | 0.99 | DRD3 (0.98) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL28259804 | 0.99 | DRD3 (0.98) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL9060252 | 0.92 | DRD3 (0.89) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL4436 | 0.91 | DRD3 (1.00) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL29356083 | 0.91 | DRD3 (1.00) | DRD3HRH1CHRM2ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4214 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026042047-A1 | COMPOSITIONS AND ARTICLES COMPRISING REVERSIBLE COMPLEXES OF CROSSLINKED CARRAGEENAN | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2026-02-26 | — | — | WO | claimed |
| WO-2026042049-A1 | DOUBLE NETWORK HYDROGEL AND PREPARATION AND APPLICATION THEREOF | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2026-02-26 | — | — | WO | claimed |
| EP-4691568-A2 | LOW-DOSE BRIMONIDINE COMBINATIONS AND USES THEREOF | Eye Therapies, LLC (US) | 2026-02-11 | — | — | EP | claimed |
| US-20250281407-A1 | LIPID DEPOT FORMULATIONS | CAMURUS AB (SE) | 2025-09-11 | — | — | US | claimed |
| EP-4590283-A1 | MUCOADHESIVE DRUG DELIVERY SYSTEMS AND METHODS OF USE | Madd Ophthalmics Ltd. (CA) | 2025-07-30 | — | — | EP | claimed |
| EP-4565206-A1 | OPHTHALMIC COMPOSITION COMPRISING PILOCARPINE AND A REDNESS REDUCTION AGENT | Bausch + Lomb Ireland Limited (IE) | 2025-06-11 | — | — | EP | claimed |
| EP-4561700-A1 | OPHTHALMIC SUSPENSION VEHICLES AND RELATED METHODS FOR PHARMACEUTICAL INGREDIENT DELIVERY | Willis, Timothy R. (US) | 2025-06-04 | — | — | EP | claimed |
| CN-222832446-U | Ketotifen fumarate tablet production equipment | 江苏鹏鹞药业有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-119604275-A | Ophthalmic suspension vehicles for drug ingredient delivery and related methods | 蒂莫西·R·威利斯 | 2025-03-11 | — | — | CN | claimed |
| CN-119235803-A | Ketotifen fumarate split-dose tablet based on 3D printing technology and preparation method thereof | 深圳市宝安区妇幼保健院 | 2025-01-03 | — | — | CN | claimed |
| WO-2001047521-A1 | USE OF KETOTIFEN AS OPHTHALMIC AGENT | NOVARTIS AG (CH) | 2001-07-05 | — | — | WO | claimed |
| WO-2001007049-A2 | OPHTHALMIC COMPOSITION COMPRISING KETOTIFEN | NOVARTIS AG (CH) | 2001-02-01 | — | — | WO | claimed |
| EP-0694310-B1 | REVERSIBLE, THERMALLY GELLING WATER-BASE MEDICINAL COMPOSITION | WAKAMOTO PHARMA CO LTD (JP) | 2000-02-16 | — | — | EP | claimed |
| CN-1048393-C | Aqueous drug composition having property of reversible thermosetting gelation | WAKAMOTO PHARMA CO LTD (JP) | 2000-01-19 | — | — | CN | claimed |
| US-5624962-A | FOR OPHTHALMIC, DERMATOLOGICAL AND BADY CAVITICAL USE | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 1997-04-29 | — | — | US | claimed |
| EP-0694310-A1 | REVERSIBLE, THERMALLY GELLING WATER-BASE MEDICINAL COMPOSITION | Wakamoto Pharmaceutical Co., Ltd. (JP) | 1996-01-31 | — | — | EP | claimed |
| CN-1097593-A | Aqueous drug composition having property of reversible thermosetting gelation | WAKAMOTO PHARMA CO LTD (JP) | 1995-01-25 | — | — | CN | claimed |
| US-5322685-A | Containing diglycerol fatty acid ester, plyvalent metal salt of fatty acid, acid salt, oil, water, active ingredient | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1994-06-21 | — | — | US | claimed |
| EP-0484529-B1 | SKIN CREAM PREPARATION FOR EXTERNAL USE | HISAMITSU PHARMACEUTICAL CO (JP) | 1994-04-27 | — | — | EP | claimed |
| EP-0551626-A1 | Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation | LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. (SI) | 1993-07-21 | — | — | EP | claimed |